旨在控制慢性淋巴细胞白血病的转化研究的架构。
On the architecture of translational research designed to control chronic lymphocytic leukemia.
机构信息
Department I of Internal Medicine, University of Cologne, Cologne, Germany.
出版信息
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):1-8. doi: 10.1182/asheducation-2018.1.1.
Abstract
Chronic lymphocytic leukemia (CLL) has been 1 of the most dynamic fields of clinical research over the last 2 decades. Important advances in understanding the biology of CLL have led to the development of new prognostic and diagnostic tools. Concurrently, several recently approved new agents hold the potential to fundamentally change the management of this leukemia and have started to improve clinical outcomes for patients. This conceptual review summarizes the major recent insights regarding the biology of CLL, the technological advances that have allowed refinement of the prognostication of the clinical course, and the new therapeutic strategies that are currently under investigation to further ameliorate the outcome for patients with CLL.
摘要
慢性淋巴细胞白血病（CLL）是过去 20 年来临床研究中最具活力的领域之一。对 CLL 生物学的深入了解带来了新的预后和诊断工具的发展。与此同时，几种最近批准的新型药物具有从根本上改变这种白血病的治疗管理方式的潜力，并开始改善患者的临床结果。这篇概念综述总结了有关 CLL 生物学的主要最新见解、允许完善临床病程预后的技术进步，以及目前正在研究的新治疗策略，以进一步改善 CLL 患者的结果。
相似文献
1
On the architecture of translational research designed to control chronic lymphocytic leukemia.旨在控制慢性淋巴细胞白血病的转化研究的架构。
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):1-8. doi: 10.1182/asheducation-2018.1.1.
2
Prognostic factors and risk stratification in chronic lymphocytic leukemia.慢性淋巴细胞白血病的预后因素与风险分层
Semin Oncol. 2016 Apr;43(2):233-40. doi: 10.1053/j.seminoncol.2016.02.009. Epub 2016 Feb 8.
3
Genetics and molecular biology of chronic lymphocytic leukemia.慢性淋巴细胞白血病的遗传学与分子生物学
Curr Treat Options Oncol. 2005 May;6(3):215-25. doi: 10.1007/s11864-005-0005-2.
4
Advances in the understanding of biology and prognosis in chronic lymphocytic leukemia.慢性淋巴细胞白血病生物学及预后认识的进展
Curr Oncol Rep. 2004 Sep;6(5):348-54. doi: 10.1007/s11912-004-0060-z.
5
B-cell chronic lymphocytic leukemia: recent progress in biology, diagnosis, and therapy.B细胞慢性淋巴细胞白血病：生物学、诊断和治疗的最新进展
Ann Oncol. 1997;8 Suppl 1:93-101.
6
Prognostic factors in chronic lymphocytic leukemia-what do we need to know?慢性淋巴细胞白血病的预后因素——我们需要了解哪些？
Nat Rev Clin Oncol. 2011 Jan;8(1):38-47. doi: 10.1038/nrclinonc.2010.167. Epub 2010 Oct 19.
7
Revision of the guidelines for diagnosis and therapy of chronic lymphocytic leukemia (CLL).慢性淋巴细胞白血病（CLL）诊断与治疗指南的修订
Best Pract Res Clin Haematol. 2007 Sep;20(3):469-77. doi: 10.1016/j.beha.2007.02.002.
8
Biology and treatment of chronic lymphocytic leukemia.慢性淋巴细胞白血病的生物学特性与治疗
Hematology Am Soc Hematol Educ Program. 2003:153-75. doi: 10.1182/asheducation-2003.1.153.
9
Diagnosing and treating chronic lymphocytic leukemia in 2009.2009 年慢性淋巴细胞白血病的诊断与治疗。
Oncology (Williston Park). 2009 Nov 15;23(12):1030-7.
10
Signaling the end of chronic lymphocytic leukemia: new frontline treatment strategies.宣告慢性淋巴细胞白血病的终结：新的一线治疗策略
Hematology Am Soc Hematol Educ Program. 2013;2013:138-50. doi: 10.1182/asheducation-2013.1.138.
引用本文的文献
1
Chronic Lymphocytic Leukemia: 2025 Update on the Epidemiology, Pathogenesis, Diagnosis, and Therapy.慢性淋巴细胞白血病：2025年流行病学、发病机制、诊断与治疗最新进展
Am J Hematol. 2025 Mar;100(3):450-480. doi: 10.1002/ajh.27546. Epub 2025 Jan 28.
2
Anti-CD37 α-amanitin-conjugated antibodies as potential therapeutic weapons for Richter syndrome.抗CD37 α-鹅膏蕈碱偶联抗体作为里氏综合征的潜在治疗武器。
Blood. 2022 Sep 29;140(13):1565-1569. doi: 10.1182/blood.2022016211.
3
ROR1 targeting with the antibody-drug conjugate VLS-101 is effective in Richter syndrome patient-derived xenograft mouse models.ROR1 靶向抗体药物偶联物 VLS-101 在里希特综合征患者来源异种移植小鼠模型中有效。
Blood. 2021 Jun 17;137(24):3365-3377. doi: 10.1182/blood.2020008404.
4
-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation.-mutated 慢性淋巴细胞白血病显示 NOTCH1 通路激活的证据，包括 CD20 下调。
Haematologica. 2021 Dec 1;106(12):3125-3135. doi: 10.3324/haematol.2020.261891.
5
Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?日本慢性淋巴细胞白血病治疗的演变：MRD 阴性是否应该成为目标？
Int J Hematol. 2020 May;111(5):642-656. doi: 10.1007/s12185-020-02867-0. Epub 2020 Apr 6.
6
A laboratory-based scoring system predicts early treatment in Rai 0 chronic lymphocytic leukemia.基于实验室的评分系统预测雷氏 0 期慢性淋巴细胞白血病的早期治疗。
Haematologica. 2020 Jun;105(6):1613-1620. doi: 10.3324/haematol.2019.228171. Epub 2019 Oct 3.
7
Relapsed/Refractory Chronic Lymphocytic Leukemia: Chemoimmunotherapy, Treatment until Progression with Mechanism-Driven Agents or Finite-Duration Therapy?复发/难治性慢性淋巴细胞白血病：化学免疫疗法、使用机制驱动药物进行持续至疾病进展的治疗还是有限疗程治疗？
Mediterr J Hematol Infect Dis. 2019 Mar 1;11(1):e2019024. doi: 10.4084/MJHID.2019.024. eCollection 2019.
本文引用的文献
1
Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trial.苯达莫司汀后继奥滨尤妥珠单抗和维奈克拉治疗慢性淋巴细胞白血病（CLL2-BAG）：多中心、开放标签、2 期试验的主要终点分析。
Lancet Oncol. 2018 Sep;19(9):1215-1228. doi: 10.1016/S1470-2045(18)30414-5. Epub 2018 Aug 13.
2
Phase 1b study of obinutuzumab, ibrutinib, and venetoclax in relapsed and refractory chronic lymphocytic leukemia.奥滨尤妥珠单抗、伊布替尼和维奈托克治疗复发/难治性慢性淋巴细胞白血病的 1b 期研究。
Blood. 2018 Oct 11;132(15):1568-1572. doi: 10.1182/blood-2018-05-853564. Epub 2018 Aug 15.
3
Biology and treatment of Richter syndrome.里希特综合征的生物学特性与治疗。
Blood. 2018 Jun 21;131(25):2761-2772. doi: 10.1182/blood-2018-01-791376. Epub 2018 Apr 24.
4
iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL.iwCLL 指南：用于 CLL 的诊断、治疗指征、疗效评估和支持性管理。
Blood. 2018 Jun 21;131(25):2745-2760. doi: 10.1182/blood-2017-09-806398. Epub 2018 Mar 14.
5
Chronic lymphocytic leukaemia.慢性淋巴细胞白血病。
Lancet. 2018 Apr 14;391(10129):1524-1537. doi: 10.1016/S0140-6736(18)30422-7. Epub 2018 Feb 21.
6
Clonal dynamics towards the development of venetoclax resistance in chronic lymphocytic leukemia.慢性淋巴细胞白血病中对维奈托克耐药性发展的克隆动力学
Nat Commun. 2018 Feb 20;9(1):727. doi: 10.1038/s41467-018-03170-7.
7
Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries.全球癌症生存趋势监测 2000-14 年（CONCORD-3）：对来自 71 个国家 322 个基于人群的登记处的 37513025 名诊断患有 18 种癌症之一的患者的个体记录进行分析。
Lancet. 2018 Mar 17;391(10125):1023-1075. doi: 10.1016/S0140-6736(17)33326-3. Epub 2018 Jan 31.
8
The evolutionary landscape of chronic lymphocytic leukemia treated with ibrutinib targeted therapy.伊布替尼靶向治疗慢性淋巴细胞白血病的进化景观。
Nat Commun. 2017 Dec 19;8(1):2185. doi: 10.1038/s41467-017-02329-y.
9
Comparison between the CLL-IPI and the Barcelona-Brno prognostic model: Analysis of 1299 newly diagnosed cases.慢性淋巴细胞白血病国际预后指数（CLL-IPI）与巴塞罗那-布尔诺预后模型的比较：对1299例新诊断病例的分析。
Am J Hematol. 2018 Feb;93(2):E35-E37. doi: 10.1002/ajh.24960. Epub 2017 Nov 23.
10
Chronic lymphocytic leukemia international prognostic index: a systematic review and meta-analysis.慢性淋巴细胞白血病国际预后指数：一项系统评价与荟萃分析
Blood. 2018 Jan 18;131(3):365-368. doi: 10.1182/blood-2017-09-806034. Epub 2017 Oct 30.
Zotero 插件